BioNTech's experimental breast cancer drug has been successful in trials.

According to the Securities Times app, BioNTech (BNTX.US) announced that a experimental drug developed in collaboration with CanSino Biologics-B (09606.HK) has achieved success in breast cancer research. This is the first successful outcome of the collaboration between the two companies.